SCHEDULE 13G/A 0001178913-24-000359 0001496201 XXXXXXXX LIVE 3 Common Shares, no par value per share 12/31/2025 0001374339 ProMIS Neurosciences Inc. 74346M406 Suite 200, 1920 Yonge Street Toronto A6 M4S 3E2 Rule 13d-1(c) Sphera Funds Management Ltd. b L3 0 180697.52 0 180697.52 180697.52 N 7.78 CO Percentage reported in Item 11 is based on approximately 2,152,444 Common Shares outstanding, following a one-for-twenty-five reverse stock split effective as of November 28, 2025 (as provided by the Issuer in Exhibit 99.1 to its Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 24, 2025), and 168,890 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share. Sphera Global Healthcare GP Ltd. b L3 0 180697.52 0 180697.52 180697.52 N 7.78 CO Percentage reported in Item 11 is based on approximately 2,152,444 Common Shares outstanding, following a one-for-twenty-five reverse stock split effective as of November 28, 2025 (as provided by the Issuer in Exhibit 99.1 to its Form 8-K filed with the SEC on November 24, 2025), and 168,890 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share. Sphera Global Healthcare Management LP. b L3 0 180697.52 0 180697.52 180697.52 N 7.78 PN Percentage reported in Item 11 is based on approximately 2,152,444 Common Shares outstanding, following a one-for-twenty-five reverse stock split effective as of November 28, 2025 (as provided by the Issuer in Exhibit 99.1 to its Form 8-K filed with the SEC on November 24, 2025), and 168,890 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share. ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada, M4S 3E2 Sphera Funds Management Ltd. Sphera Global Healthcare GP Ltd. Sphera Global Healthcare Management LP Address of the Principal Business Office of each of the reporting persons is: 4 Itzhak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel Each of the reporting person is organized under the laws of the State of Israel Y See row 9 of cover page of each reporting person. The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows: * 31,637.80 warrants, with each warrant currently exercisable into one Common Share, representing a total of 1.36% of the total Common Shares outstanding, are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company"). * 11,807.48 Common Shares and 137,252.24 warrants, with each warrant currently exercisable into one Common Share, together representing a total of 6.42% of the total Common Shares outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its investment management authority to the Management Company. The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd. This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group. Incorporated by reference to Item 11 of the cover page for each reporting person. Percentage reported in Item 11 for each reporting person is based on approximately 2,152,444 Common Shares outstanding, following a one-for-twenty-five reverse stock split effective as of November 28, 2025 (as provided by the Issuer in Exhibit 99.1 to its Form 8-K filed with the SEC on November 24, 2025), and 168,890 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share. Incorporated by reference to Item 5 of the cover page for each reporting person. Incorporated by reference to Item 6 of the cover page for each reporting person. See also note in Item 4(a) above. Incorporated by reference to Item 7 of the cover page for each reporting person. Incorporated by reference to Item 8 of the cover page for each reporting person. See also note in Item 4(a) above. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1: Joint Filing Agreement by and among the reporting persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on August 30, 2023) Sphera Funds Management Ltd. /s/ Adi Hanetz 02/05/2026 Sphera Global Healthcare GP Ltd. /s/ Adi Hanetz 02/05/2026 Sphera Global Healthcare Management LP. /s/ Adi Hanetz 02/05/2026